TH23722A - The conjugates of metal compounds and oligonucleotides are specifically bound to specific target structures These conjugated substances Its applications in the diagnosis of NMR as well as its manufacturing processes - Google Patents
The conjugates of metal compounds and oligonucleotides are specifically bound to specific target structures These conjugated substances Its applications in the diagnosis of NMR as well as its manufacturing processesInfo
- Publication number
- TH23722A TH23722A TH9501001688A TH9501001688A TH23722A TH 23722 A TH23722 A TH 23722A TH 9501001688 A TH9501001688 A TH 9501001688A TH 9501001688 A TH9501001688 A TH 9501001688A TH 23722 A TH23722 A TH 23722A
- Authority
- TH
- Thailand
- Prior art keywords
- oligonucleotides
- conjugates
- nmr
- diagnosis
- applications
- Prior art date
Links
- 108091034117 Oligonucleotide Proteins 0.000 title claims abstract 6
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 title claims abstract 5
- 239000000126 substance Substances 0.000 title abstract 2
- 238000003745 diagnosis Methods 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 150000002736 metal compounds Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 6
- 101710163270 Nuclease Proteins 0.000 claims abstract 2
- 230000015556 catabolic process Effects 0.000 claims 1
- 238000006731 degradation reaction Methods 0.000 claims 1
- 238000006073 displacement reaction Methods 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 238000012986 modification Methods 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Abstract
การประดิษฐ์นี้เกี่ยวข้องกับโกนิวคลีโอไทด์คอนจูเกตที่ได้รับการดัดแปลงทางเคมีที่มีสารรวม ตัวหรือสารประกอบที่จับยึดโดยส่วนเชื่อมต่อโกนิวคลีโอไทด์ ในกรณีนี้โอลิโกนิวคลีโอไทด์จะได้รับ การดัดแปลงในลักษณะที่ทำให้ป้องกันหรืออย่างน้อยที่สุดยับยั้งการสลายตัวโดยนิวคลีเอสตามธรรมชาติ อย่างมีนัยสำคัญ อนุมูลโอลิโกนิวคลีโอไทด์สามารถจับยึดอย่างจำเพาะและด้วยสัมพรรคภาพการจับยึด ที่สูงต่อโครงสร้างเป้าหมายและดังนั้นจึงสามารถให้ผลการรักษาหรือการวินิจฉัยที่จำเพาะโดยสารจับรวม หรือสารประกอบที่จับยึดด้วย The invention involved a chemically modified conjugated gonucleotide containing a combined substance. The body or compound held by the gonucleotide junction. In this case, the oligonucleotides are obtained. Modifications in a manner that prevent or at least inhibit decay by natural nuclease. Significantly Oligo nucleotides are able to bind specifically and by relative affinity. It is highly dependent on the target structure and therefore can provide specific therapeutic or diagnostic results by combined capture. Or the compound holding it with
Claims (2)
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TH23722A true TH23722A (en) | 1997-02-25 |
Family
ID=
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69829562D1 (en) | HYDROCYANATION METHODS AND MULTIPOSE PHOSPHIT LIGANDS AND CATALYST COMPOSITIONS FROM NICKEL USEFUL THEREOF | |
| EP1379987A4 (en) | COMPUTER-SPECIFIED FERTILIZER APPLICATION FOR AGRICULTURAL FIELDS | |
| WO2001074898A8 (en) | Charged compounds comprising a nucleic acid binding moiety and uses therefor | |
| WO2003059251A3 (en) | Antibody targeting compounds | |
| MX9709913A (en) | Structurally determined metallo-constructs and applications. | |
| BR9709942A (en) | Use of a compound pharmaceutical composition packaging and treatment process of human or non-human animal organism to combat or prevent conditions associated with the presence of free radicals in the body | |
| MA30689B1 (en) | LEPTOMYCIN DERIVATIVES | |
| EP1195168A3 (en) | Ternary radiopharmaceutical complexes | |
| BR9908610A (en) | Compound, process to produce the same, pharmaceutical composition, use of the compound, processes to inhibit the production of nitric oxide and / or cytokine in mammals, and to prevent or treat heart disease, autoimmune disease or septic shock in mammals, and, for medications | |
| DE60042369D1 (en) | CHEMICAL PROGRAMMABLE IMMUNITY | |
| ATE202569T1 (en) | PRODRUG OLIGONUCLEOTIDES | |
| TH23722A (en) | The conjugates of metal compounds and oligonucleotides are specifically bound to specific target structures These conjugated substances Its applications in the diagnosis of NMR as well as its manufacturing processes | |
| DE69723242D1 (en) | TERNARY RADIOPHARMACEUTICAL COMPLEXES | |
| WO1998000435A3 (en) | Oligonucleotide linker and techniques involving immobilized and linked oligonucleotides | |
| NO970141D0 (en) | Conjugates of metal complexes and oligonucleotides, agents containing the conjugates, their use in radiodiagnosis, and their method of preparation | |
| EP1153596A3 (en) | Hair treatment compositions | |
| WO2007064661A3 (en) | Bifunctional metal chelating conjugates | |
| WO2002049672A3 (en) | Conjugates of antibodies and anticancer drugs | |
| TH24679A (en) | Coljugate made from metal compounds and oligonucleotides. Substances with conjugated Using it in radiological diagnosis As well as its manufacturing processes | |
| WO2002038566A3 (en) | Carbene porphyrins and carbene porphyrinoids for use in medical diagnosis and treatment | |
| ATE123228T1 (en) | MYOCARDIAL TECHNETIUM COMPLEX CONNECTIONS AND METHOD FOR THE PRODUCTION THEREOF. | |
| WO2005076732A3 (en) | Peptide-pna chimera targeting inducible nitric oxide synthase | |
| WO2003059394A3 (en) | Composition for transporting oligonucleotides through the blood brain barrier and their use for treating central nervous system diseases | |
| ZA955894B (en) | Conjugates of metal complexes and oligonucleotides which specifically bond to specific target structures agents containing these conjugates their use in nmr diagnosis as well as process for their production | |
| Khachatryan et al. | Synthesis of novel targeted molecules for the diagnosis and treatment of cancer: combination of cytostatics with metal complexes |